Eyeworld

EW MEETING REPORTER 128 March 2011 Practice Management Track During the final day of ASOA's Practice Management Track, experts talked to administrators about med- ical office technology and its future. How to implement electronic health records and demonstrate their "meaningful use" was the hot topic of the morning. The American Recovery and Reinvestment Act of 2009 author- ized the Centers for Medicare & Medicaid Services (CMS) to give fi- nancial incentives to eligible profes- sionals and hospitals that demonstrate "meaningful use" of EHRs. Under the program, practi- tioners who adopt electronic health records may qualify for up to $44,000 over 5 years. Alternatively, Medicare will drop payments start- ing in 2015 to providers who have not adopted EHR technology and demonstrated its meaningful use. To participate, all doctors are required to register on the EHR Incentive website, be enrolled in Medicare FFS, MA, or Medicaid, have a National Provider Identifier, and use certified EHR technology. To achieve meaningful use, a practice must report on 15 manda- tory core objectives. "Many of them are primary care focused," said Nancey McCann, ASCRS•ASOA di- rector of government relations. Those objectives include using com- puterized physician order entry for Reporting live from ASCRS Winter Update, Palm Beach, Fla. by Jena Passut and Faith A. Hayden VisionBlue TM is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens. 1 VisionBlue TM is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. It is recommended that after injection all excess VisionBlue TM be immediately removed from the eye by thorough irrigation of the anterior chamber. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non stained lens cortex and inner lens material. 1 VisionBlue TM is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye because the dye may be absorbed by the IOL and stain the IOL. Adverse reactions reported following use of VisionBlue TM include inadvertent staining of the posterior lens capsule or vitreous face. Staining of the posterior lens capsule or vitreous face is generally self limited, lasting up to one week. Rx Only 1 Melles GJR, de Waard PWT, Pameyer JH, Houdijn Beekhuis W, Trypan blue capsule staining to visualize the capsulorhexis in cataract surgery. J Cataract Refractive Surgery 1999; 25:7-9 Please see adjacent page for brief prescribing information. 0.06% TRYPAN BLUE OPHTHALMIC SOLUTION ORDER INFORMATION VisionBlue TM is available in sterile packs of 10 syringes of 0.5ml/box Call: (800) 75-DUTCH or (603) 778-6929 E-mail: sales@dutchophthalmicusa.com D.O.R.C. International B.V. Scheijdelveweg 2 3214 VN Zuidland The Netherlands Phone: +31 181 45 80 80 Fax: +31 181 45 80 90 E-mail: sales@dorc.nl Dutch Ophthalmic USA 10 Continental Drive Bldg 1, Exeter, NH 03833, U.S.A. Phone: +1 800-75-DUTCH or +1 603-778-6929 Fax: +1 603-778-0911 E-mail: sales@dutchophthalmicusa.com continued from page 127

• Cover